New Two-Drug attack tested to shrink cervical tumors before surgery
NCT ID NCT07055399
Summary
This study is testing whether a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus standard chemotherapy can shrink tumors in patients with locally advanced cervical cancer before they have surgery. The goal is to see if this preoperative treatment leads to better surgical outcomes and longer survival. The trial will enroll 43 patients to evaluate how well the tumors respond and monitor the safety of this approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fujian Cancer Hospital
RECRUITINGFuzhou, Fujian, 350014, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.